Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

NCT05118958 PHASE1 COMPLETED

This is a 3 part, phase 1 crossover study in healthy subjects to evaluate the pharmacokinetic profile of KVD824 following single and multiple doses of novel KVD824 modified-release formulations compared with a reference KVD824 immediate release formulation.

Details

Lead sponsor	KalVista Pharmaceuticals, Ltd.
Phase	PHASE1
Status	COMPLETED
Enrolment	37
Start date	Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hereditary Angioedema

Interventions

• KVD824 Prototype 1 modified-release tablet
• KVD824 Prototype 2 modified-release tablet
• KVD824 Immediate-Release Capsule
• Placebo to KVD824 Prototype 1
• KVD824 Prototype 3 modified-release tablet

Countries

United Kingdom